Clinical Trial Update: Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease [Phase 2]

View source ↗

Summary

A Phase 2 dose-escalation trial evaluating icotinib in patients with advanced non-small cell lung cancer who had stable disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: NSCLC | Phase 2 | Status: UNKNOWN